Senseonics’ Eversense Continuous Glucose Monitoring (CGM) system provides real-time glucose monitoring every 5 minutes for up to 90 days. The system consists of an implantable fluorescence-based sensor, a smart transmitter, and a mobile app for displaying glucose values, trends, and alerts. This supplement expands indications for the Eversense CGM system to replace fingerstick blood glucose testing for diabetes.
PrinterPrezz achieved ISO 13485:2016 certification. Its Medifacturing – connecting medicine and manufacturing – combines 3D printing, nanotechnologies, and surgical expertise for next-generation medical devices.
Transparency in MDR
The U.S. Food and Drug Administration’s (FDA) Center for Devices and Radiological Health (CDRH) continues to take steps to update its Medical Device Reporting (MDR) program and medical device transparency, according to a written statement from Dr. Jeffrey E. Shuren, M.D., J.D., director, FDA CDRH.
Since 2017, the FDA has gradually sunset the Alternative Summary Reporting (ASR) program to streamline medical device reporting as the Voluntary Malfunction Summary Reporting (VMSR) program was implemented. To formally end the program, revocation letters were issued to 13 remaining manufacturers with ASR exemptions that covered dental implants, implantable cardiac defibrillators, and pacemaker electrodes.
The VMSR Program reflects a pilot program conducted in response to changes made in the FDA Amendments Act of 2007 and goals agreed to as part of the Medical Device User Fee Amendments of 2017 (MDUFA IV) process. The FDA implemented the VMSR Program after a pilot study demonstrated the value of the program to public health.
Finally, the FDA also intends to make its Manufacturer and User Facility Device Experience (MAUDE) database and MDR data more user-friendly to increase transparency in medical device reporting, working since 2012 to develop the National Evaluation System for health Technology (NEST) – to systematically use real-world data to rapidly identify and help address safety signals once devices are on the market through active surveillance.